about
Secukinumab for ankylosing spondylitis and psoriatic arthritisBeyond the joint: Subclinical atherosclerosis in rheumatoid arthritis.Elderly psoriatic arthritis patients on TNF-α blockers: results of an Italian multicenter study on minimal disease activity and drug discontinuation rate.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.The role of IL-17 in the treatment of psoriatic arthritis.Mesenchimal stem cells: a possible role in the pathogenesis and treatment of spondyloarthritis.Patient's Global Assessment as an Outcome Measure for Psoriatic Arthritis in Clinical Practice: A Surrogate for Measuring Low Disease Activity?Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.Assessment of subclinical atherosclerosis in ankylosing spondylitis: correlations with disease activity indices.Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study.Unmet Needs in Axial Spondyloarthritis.An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment.The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.Psoriatic arthritis: is it time to treat-to-target or target to treat?Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications.Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study.Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.What Should Be the Primary Target of “Treat to Target” in Psoriatic Arthritis?Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational studyAssessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor InhibitorsDefining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease InstrumentsMinimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α DrugsNew approved drugs for psoriatic arthritisRemission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor-α Drugs: An Italian Multicenter StudyPredictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugsÉvaluation de l’enthésite dans le rhumatisme psoriasique grâce à l’écho-Doppler énergie. Étude multicentriqueClinical and imaging assessment of peripheral enthesitis in ankylosing spondylitisPower Doppler ultrasonographic evaluation of enthesitis in psoriatic arthritis. A multi-center studyPsoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?Occult axial involvement in patients with psoriatic arthritis mutilans: a case reportUltrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE StudyNew Insights in Physical Therapy and Rehabilitation in Axial Spondyloarthritis: A ReviewDr. Lubrano, et al reply
P50
Q28071474-4F19BE1F-93AE-40A8-B49D-990A9956360DQ38230867-39A63D72-AF21-4CB8-A2EB-0255CCC4D736Q38739243-69420A34-C1C8-4673-B381-D94A88FC8342Q38766379-B731CB29-2A2B-46B5-A6A6-9CE526A117E9Q39293096-2A9B8334-9E44-416B-B8F4-BC2EB4ED6160Q39324809-2F958063-30C8-431D-8C3D-304E59C4B2AFQ40368544-2267AC3F-5A48-425D-8B90-EACD06488351Q40634737-EC40161D-0460-41E7-967C-EF1180BDA2CFQ47942295-437E3D0B-90CB-41D5-BF4C-C49C38F025EAQ47954115-3FE0028C-40A8-4313-B509-7A8787C569F5Q48287506-569A6430-6AB9-4CA0-B6DD-BACC98B0830CQ48367391-3DC7E255-7522-4DF9-9206-9B1DF2B6C4D5Q48502343-851CC644-8CEF-455E-B8D1-8638177A9F69Q48620762-99570851-055B-4542-AC71-5C6DB26C61C3Q51724801-3303FDCC-F5E6-40FD-BB9F-EA14014BBCDCQ52394125-78B3D2D6-8A51-4A64-A31B-BD80DBA1A304Q52848191-3E31D3A5-D267-4E86-86C0-F8D08FC9919EQ53251949-6C02F3D4-4721-4DC9-A9EA-53EC6ECB13C6Q58417462-2575EB69-2AC1-4005-AB2F-491C76CCFC54Q61633956-754E011A-84AD-4649-9374-F27DBF1D7169Q61633958-A7B47EB1-B135-4F5B-93BD-20E624EB66C7Q61633959-84040D77-D0A7-4F18-843B-5B53F11BAC6FQ61633960-7F4E6746-FB06-45EA-8E52-8EDA3E2B34C4Q61633961-F5DDD325-147B-40C4-BBA2-AE5726746836Q61633962-FBBB05C2-70C2-4050-9B4A-1038D2FC8E1EQ61633963-91615753-8A74-429C-9DCE-61A94411664CQ61633964-0096F316-85BE-4FF8-BEC1-DD8F0BC5729EQ61633965-77A3857C-B959-4B29-A7B1-7B78395C13DEQ61633967-2B0A5890-4C80-4100-8558-FF9A5DEC40E0Q91061488-D8B36DEE-E36D-447A-B510-077790AE75D3Q91916278-53B64936-04AF-4F4A-8E8F-8AE4D8F5A020Q92402849-ECCF2121-CE4F-4031-BC06-CD71443DADB9Q92608550-93C979D1-429F-4BAC-941D-36A9DD943B4DQ94482428-BA0166EA-7D94-4389-A331-5F0AA33FA8D9
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Fabio Massimo Perrotta
@ast
Fabio Massimo Perrotta
@en
Fabio Massimo Perrotta
@es
Fabio Massimo Perrotta
@nl
type
label
Fabio Massimo Perrotta
@ast
Fabio Massimo Perrotta
@en
Fabio Massimo Perrotta
@es
Fabio Massimo Perrotta
@nl
prefLabel
Fabio Massimo Perrotta
@ast
Fabio Massimo Perrotta
@en
Fabio Massimo Perrotta
@es
Fabio Massimo Perrotta
@nl
P106
P1153
36723939700
P21
P31
P496
0000-0003-3771-5205